Moreover, STAT3 increases chemoresistance of melanomas to selective inhibitors of BRAF, which are exploited in the treatment of unresectable or metastatic melanoma with a BRAF-V600 gain-of-function mutation [48]. This evidence concerns the gene STAT3 and melanoma.